Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02861183
Other study ID # OVT 16-01
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date September 2025
Est. completion date October 2027

Study information

Verified date November 2022
Source Anika Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of Sodium Hyaluronate to provide Symptomatic Relief of Lateral Epicondylosis (Tennis Elbow).


Description:

The objective of this study is to assess the safety and effectiveness of two weekly peri-osteotendinous injections of OVT for relief of pain in patients with lateral epicondylosis in a multi-center, randomized, double-blind, placebo controlled superiority study. A total of 186 subjects will be enrolled at up to 20 centers in the US and Europe. The randomization ratio will be 2:1 (2 OVT subjects: 1 placebo subject). The entire study duration from first subject in to last subject out is approximately one year. The enrollment phase is approximately 6 months with a follow-up phase of 6 months. Visits are scheduled at baseline, 1 week, 4 weeks, 12 weeks, 18 weeks, and 26 weeks. Study injections will be given at the baseline and 1 week visits.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date October 2027
Est. primary completion date April 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Male or female between 18 and 65 years of age 2. Clinical diagnosis of unilateral lateral epicondylosis defined as: 1. Pain reproducible on palpation of the lateral epicondyle / common extensor origin; and 2. Pain reproducible during resisted wrist extension 3. Subject is symptomatic for at least 6 weeks 4. Subject has pain in the index lateral epicondyle after grip strength testing that measures = 40 mm on a 100 mm VAS 5. Subject must be willing to abstain from other pharmacological and surgical treatments of the index elbow for the duration of the study 6. Subject is willing to discontinue all systemic and/or topical analgesics including NSAIDs, (except the rescue medication oral acetaminophen/paracetamol), for the treatment of lateral epicondylosis at least seven days before the initial treatment injection and through the completion of the study 7. If pain medication is needed during the study, subject is willing to use only acetaminophen/paracetamol (up to a maximum of 3.0 grams per day per the package insert) for the treatment of elbow pain for the duration of the study 8. At least twenty four hours prior to the Baseline Visit and each follow-up visit, the subject must discontinue use of acetaminophen/paracetamol, if used 9. Subject is able to understand and comply with the requirements of the study and voluntarily provides consent Exclusion Criteria: 1. Subjects with a history of hypersensitivity to any of the ingredients in the hyaluronan or an inability to tolerate acetaminophen/paracetamol 2. Subjects in which the investigator believes the anatomical landmarks for injection are unable to be adequately identified 3. Subjects who have a history of surgery to the intra-articular joint of the index elbow and/or history of index elbow dislocation 4. Any diagnosed pathology or trauma that causes pain or symptoms in the index elbow other than lateral epicondylosis (e.g. intra-articular pathology, ligament injury, cervical radiculopathy, radial tunnel syndrome, osteochondral radiocapitellar lesion or posterolateral elbow plica, pain starting after a motor vehicle accident) 5. Hyaluronic acid injections in the index elbow within the last 6 months 6. Steroid injections in the index elbow within the last 3 months 7. Infections or skin diseases in the area of the injection site or elbow joint 8. Known inflammatory or autoimmune disorders, or other pre-existing medical conditions that, in the opinion of the investigator, could impact healing or affect the ability of the subject to complete the study and comply with the study requirements 9. Subject is taking medications at the time of consent which could interfere with the treatment procedure, healing and/or assessments. This includes but is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet treatment and opioid analgesics. Low dose aspirin (81 mg) used for cardiovascular protection is allowed if a stable regimen is maintained for the duration of the study. 10. Subject is receiving or in litigation for worker's compensation 11. Subject is a woman who is pregnant or breastfeeding at the screening visit or a woman of child bearing potential who refuses to use effective contraception during the course of the study 12. Subject was involved in any other research study involving an investigational product, or a new application of an approved product, within 60 days of signing the Informed Consent Form (ICF)

Study Design


Related Conditions & MeSH terms


Intervention

Device:
OVT (Sodium Hyaluronate)
A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
Saline
A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Anika Therapeutics, Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in elbow pain after grip as measured by a 100 mm Visual Analog Scale (VAS) at 12 weeks comparing the OVT group to the saline control group Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. 12 weeks post injection
Secondary The change from baseline in elbow pain after grip as measured by a 100 mm VAS at 4, 18, and 26 weeks comparing the OVT group to the saline control group Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. 4, 18, 26 weeks post-injection
Secondary The change from baseline in elbow pain after grip as measured by a 100 mm VAS through 4-26 weeks using a longitudinal model comparing the OVT group to the saline control group Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. 26 weeks post-injection
Secondary The change from baseline in elbow pain at rest as measured by a 100 mm VAS through 4-26 weeks using a longitudinal model comparing the OVT group to the saline control group Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. 26 weeks post-injection
Secondary The change from baseline in elbow pain as measured by the Patient-Rated Tennis Elbow Evaluation (PRTEE) Pain and Function Questionnaire through 4-26 weeks using a longitudinal model comparing the OVT group to the saline control group Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. 26 weeks post-injection
Secondary The change from baseline in elbow pain as measured by the Disabilities of Arm, Shoulder, and Hand (DASH) Questionnaire through 4-26 weeks using a longitudinal model comparing the OVT group to the saline control group Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. 26 weeks post-injection
Secondary The change from baseline in Grip Strength using a hydraulic hand dynamometer at 4, 12, 18, and 26 weeks comparing the OVT group to the saline control group Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. 4,12,18 and 26 weeks post-injection
Secondary The change from baseline in rescue medication consumption (acetaminophen/ paracetamol) through weeks 4-26 comparing the OVT group to the saline control group Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. 26 weeks post-injection
Secondary The incidence, timing, severity, and relationship to treatment of all adverse events will be classified using MedDRA. Pain After Grip score was determined by asking the subject "How much pain do you have in your STUDY elbow right now?" and recording their response by placing a mark along a 100mm VAS scale with 0mm=no pain and 100mm=extreme pain. A negative value for change from baseline indicated a reduction in pain. A greater negative value indicates a better outcome. During injection, 4, 12, 18 and 26 weeks post-injection
See also
  Status Clinical Trial Phase
Recruiting NCT02304952 - Eccentric Exercise or Radiofrequent Microtenotomy as Treatment of Lateral Epicondylalgia N/A
Completed NCT02596659 - Effectiveness of Radial Extracorporeal Shockwave Therapy on Tennis Elbow N/A
Completed NCT00674622 - Prolotherapy for the Treatment of Chronic Lateral Epicondylitis Phase 2/Phase 3
Completed NCT06206109 - The Effect of Tendon Tears on Lateral Epicondylitis
Recruiting NCT04442321 - Ultrasound-Guided Percutaneous Electrical Stimulation on Radial Nerve in Patients With Lateral Epicondylalgia N/A
Not yet recruiting NCT04382144 - Levobupivacaine Versus Liposomal Bupivacaine (Exparel®) for Treatment of Pain and Disability in Lateral Epicondylitis Phase 4
Recruiting NCT03863847 - A Neurofeedback Treatment for Chronic Musculoskeletal Pain N/A
Completed NCT04576195 - Immediate Neurophysiological Effects of PENS on Radial Nerve in Patients With Lateral Epicondylalgia N/A
Recruiting NCT02343809 - Diacutaneous Fibrolysis on Lateral Epicondylitis Phase 3
Completed NCT05084664 - Effect of Premodulated Current Versus Diadynamic Current On the Management of Tennis Elbow. N/A
Completed NCT05039827 - Mobilition With Movement and Soft Tissue Mobiiztion in Tennis Elbow N/A
Recruiting NCT00395616 - Comparison Between Type A Botulinum Toxin Injection and Corticosteroid Injection in the Treatment of Tennis Elbow N/A
Completed NCT00130949 - ALGRX 4975 in the Treatment of Tennis Elbow Phase 2
Recruiting NCT06116175 - Lateral Epicondylitis Continuous Radiofrequency Microtenotomy N/A
Recruiting NCT05326763 - Functional and Electromyographical Changes After PRP or Dextrose Injection in Chronic Lateral Epicondylitis Phase 3
Completed NCT04454060 - Study on the Development of Arthroscopic Treatment of Refractory Tennis Elbow
Enrolling by invitation NCT04445727 - Efficacy of Vitamin C Supplement vs Spinal Manipulation to Treatment in Lateral Epicondylitis N/A
Completed NCT04454047 - Extracapsular Arthroscopic Treatment for Refractory Tennis Elbow——Mid-and-short Term Retrospective Study of 50 Cases
Recruiting NCT06382805 - Comparison of the Effects of Kinesio Tape and High-intensity Laser Therapy in Lateral Epicondylitis N/A
Completed NCT04395417 - Injection Therapy in Patients With Lateral Epicondylitis N/A